Previous 10 | Next 10 |
2024-01-02 12:32:09 ET More on COVID vaccine makers BioNTech's Strategic Shift: Diversifying Into Cancer Therapeutics Novavax: Do Not Expect A Turnaround In 2024 BioNTech's COVID-19 Success Paves The Way For A Strong Drug Pipeline Moderna upgraded at Oppenhei...
Originally published in Alkermes September 2023 Corporate Responsibility Report NORTHAMPTON, MA / ACCESSWIRE / December 27, 2023 / Our employees are the foundation upon which our business is built. Their expertise, intelligence and creativity drive our innovation, and their passion and comm...
NORTHAMPTON, MA / ACCESSWIRE / December 20, 2023 / Alkermes Originally published in Alkermes September 2023 Corporate Responsibility Report Board of Directors Our Board is currently comprised of eleven members, each of whom has a term expiring at the Company's 2024 annual general meeting o...
NORTHAMPTON, MA / ACCESSWIRE / December 18, 2023 / Alkermes Originally published in Alkermes September 2023 Corporate Responsibility Report Ethics and Compliance Integrity is a core Alkermes value and the foundation of the way we do business. Alkermes is dedicated to upholding legal, regul...
NORTHAMPTON, MA / ACCESSWIRE / December 14, 2023 / Alkermes Originally published in Alkermes September 2023 Corporate Responsibility Report Employee engagement remained a top priority for the Company throughout 2022. As many of our office-based employees have adapted to a hybrid work model, w...
2023-12-14 06:57:08 ET More on Alkermes, Novo Nordisk: Novo Nordisk: Latest Insights Confirm Exceptionally Bullish Opportunity Novo Nordisk: Plenty More Room To Run Despite Its Hefty Valuation Alkermes: A Complicated Story Right Now Lybalvi: Wei...
Alkermes plc Announces Agreement to Sell Athlone, Ireland Facility to Novo Nordisk PR Newswire DUBLIN , Dec. 14, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it has entered into a definitive agreement to sell its development and manuf...
NORTHAMPTON, MA / ACCESSWIRE / December 11, 2023 / Alkermes Originally published in Alkermes September 2023 Corporate Responsibility Report We have developed and now manufacture and commercialize proprietary medicines for the treatment of alcohol dependence, opioid dependence, schizophrenia ...
Uber Technologies, Jabil and Builders FirstSource Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600 Uber Technologies, Jabil and Builders FirstSource Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600 PR Newswire ...
2023-12-01 10:17:15 ET The UBS pharma equity team is out with a quant list of most crowded stocks on the long and short side. Crowding is a sentiment metric that basically measure popularity in positioning (long or short). It indicates if a stock has a significantly above-average number...
News, Short Squeeze, Breakout and More Instantly...
Alkermes plc (ALKS) is expected to report $0.64 for Q2 2024 Acerinox ADR (ANIOY) is expected to report for Q2 2024 Allegion plc (ALLE) is expected to report $1.77 for Q2 2024 Deutsche Bank AG (DB) is expected to report $0.43 for Q2 2024 Pathward Financial Inc. (CASH) is expected t...
Alkermes plc Reports Second Quarter 2024 Financial Results PR Newswire — Second Quarter Revenues of $399.1 Million — — Net Sales of Proprietary Products Increased Approximately 16% Year-Over-Year — — GAAP Net Income from C...
2024-07-22 10:45:03 ET Enbridge Inc (ENB) ENB is trading UP for the last 5 days, and it at trading at $36.59 with volume of 731,965 and a one day change of $0.05 (0.14%). Enbridge Inc has a 52-week low of 31.03 and a 52-week high of $38.36. The business's 50-day moving average price...